Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York. more
Time Frame | TARA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -10.08% | -3.39% | 0.2% |
1-Month Return | 143.29% | -1.92% | 2.72% |
3-Month Return | 208.79% | -10.54% | 7.31% |
6-Month Return | 120.39% | -4.47% | 10.44% |
1-Year Return | 213.97% | 4.06% | 27.53% |
3-Year Return | -15.74% | 0.94% | 30.88% |
5-Year Return | -52.37% | 36.67% | 89.21% |
10-Year Return | -98.6% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 16.00K | 196.00K | 1.17M | 247.00K | 341.00K | [{"date":"2019-12-31","value":1.37,"profit":true},{"date":"2020-12-31","value":16.8,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":21.17,"profit":true},{"date":"2023-12-31","value":29.22,"profit":true}] |
Gross Profit | (16.00K) | (196.00K) | (1.17M) | (247.00K) | (341.00K) | [{"date":"2019-12-31","value":-1600000,"profit":false},{"date":"2020-12-31","value":-19600000,"profit":false},{"date":"2021-12-31","value":-116700000,"profit":false},{"date":"2022-12-31","value":-24700000,"profit":false},{"date":"2023-12-31","value":-34100000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 15.25M | 34.44M | 47.49M | 37.55M | 43.61M | [{"date":"2019-12-31","value":32.12,"profit":true},{"date":"2020-12-31","value":72.53,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":79.06,"profit":true},{"date":"2023-12-31","value":91.84,"profit":true}] |
Operating Income | (15.25M) | (34.44M) | (47.49M) | (67.06M) | (43.61M) | [{"date":"2019-12-31","value":-1525400000,"profit":false},{"date":"2020-12-31","value":-3444400000,"profit":false},{"date":"2021-12-31","value":-4748900000,"profit":false},{"date":"2022-12-31","value":-6706200000,"profit":false},{"date":"2023-12-31","value":-4361300000,"profit":false}] |
Total Non-Operating Income/Expense | - | 932.00K | 474.00K | 2.20M | 6.08M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":15.32,"profit":true},{"date":"2021-12-31","value":7.79,"profit":true},{"date":"2022-12-31","value":36.2,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (14.99M) | (33.98M) | (47.25M) | (65.95M) | (40.42M) | [{"date":"2019-12-31","value":-1499200000,"profit":false},{"date":"2020-12-31","value":-3397800000,"profit":false},{"date":"2021-12-31","value":-4725200000,"profit":false},{"date":"2022-12-31","value":-6595200000,"profit":false},{"date":"2023-12-31","value":-4042000000,"profit":false}] |
Income Taxes | (262.00K) | (466.00K) | (117.00K) | (1.14M) | (341.00K) | [{"date":"2019-12-31","value":-26200000,"profit":false},{"date":"2020-12-31","value":-46600000,"profit":false},{"date":"2021-12-31","value":-11700000,"profit":false},{"date":"2022-12-31","value":-113700000,"profit":false},{"date":"2023-12-31","value":-34100000,"profit":false}] |
Income After Taxes | - | (33.51M) | (47.13M) | (64.81M) | (40.08M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-3351200000,"profit":false},{"date":"2021-12-31","value":-4713500000,"profit":false},{"date":"2022-12-31","value":-6481500000,"profit":false},{"date":"2023-12-31","value":-4007900000,"profit":false}] |
Income From Continuous Operations | (14.99M) | (33.98M) | (47.25M) | (65.95M) | (69.17M) | [{"date":"2019-12-31","value":-1499200000,"profit":false},{"date":"2020-12-31","value":-3397800000,"profit":false},{"date":"2021-12-31","value":-4725200000,"profit":false},{"date":"2022-12-31","value":-6595200000,"profit":false},{"date":"2023-12-31","value":-6916600000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (14.73M) | (33.51M) | (47.13M) | (64.81M) | (40.42M) | [{"date":"2019-12-31","value":-1473000000,"profit":false},{"date":"2020-12-31","value":-3351200000,"profit":false},{"date":"2021-12-31","value":-4713500000,"profit":false},{"date":"2022-12-31","value":-6481500000,"profit":false},{"date":"2023-12-31","value":-4042000000,"profit":false}] |
EPS (Diluted) | (30.15) | (4.73) | (4.21) | (3.99) | (3.57) | [{"date":"2019-12-31","value":-3015,"profit":false},{"date":"2020-12-31","value":-473,"profit":false},{"date":"2021-12-31","value":-421,"profit":false},{"date":"2022-12-31","value":-399,"profit":false},{"date":"2023-12-31","value":-357,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
TARA | |
---|---|
Cash Ratio | 9.43 |
Current Ratio | 9.85 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
TARA | |
---|---|
ROA (LTM) | -28.11% |
ROE (LTM) | -45.91% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
TARA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.13 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.87 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
TARA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 2.32 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 0.74 |
Protara Therapeutics Inc (TARA) share price today is $5.065
Yes, Indians can buy shares of Protara Therapeutics Inc (TARA) on Vested. To buy Protara Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TARA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Protara Therapeutics Inc (TARA) via the Vested app. You can start investing in Protara Therapeutics Inc (TARA) with a minimum investment of $1.
You can invest in shares of Protara Therapeutics Inc (TARA) via Vested in three simple steps:
The 52-week high price of Protara Therapeutics Inc (TARA) is $6.88. The 52-week low price of Protara Therapeutics Inc (TARA) is $1.59.
The price-to-earnings (P/E) ratio of Protara Therapeutics Inc (TARA) is
The price-to-book (P/B) ratio of Protara Therapeutics Inc (TARA) is 2.32
The dividend yield of Protara Therapeutics Inc (TARA) is 0.00%
The market capitalization of Protara Therapeutics Inc (TARA) is $192.88M
The stock symbol (or ticker) of Protara Therapeutics Inc is TARA